The UK big pharma company will pay $1.2bn upfront for Boston’s subsidiary BP Asset IX, which will give the company access to efimosfermin. GSK has also agreed to pay additional milestone ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD) ...

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

GSK will acquire liver-disease treatment efimosfermin from Boston Pharmaceuticals for up to $2 billion to expand its portfolio. The British pharma giant said Wednesday that it will pay the U.S ...

Only a few days out of the European Association for the Study of the Liver annual meeting, the metabolic dysfunction-associated steatohepatitis (MASH) space continues to grab headlines, with GSK plc ...

GSK is also set to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2B in cash.

LONDON — GSK said Wednesday it would purchase an experimental liver disease medicine from Boston Pharmaceuticals for $1.2 billion upfront, seeking to build up its pipeline of future ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

GSK is also set to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2B in cash.